Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

P-Cadherin (CDH3) is overexpressed in colorectal tumors and has potential as a serum marker for colorectal cancer monitoring.

Kumara HMCS, Bellini GA, Caballero OL, Herath SAC, Su T, Ahmed A, Njoh L, Cekic V, Whelan RL.

Oncoscience. 2017 Oct 21;4(9-10):139-147. doi: 10.18632/oncoscience.370. eCollection 2017 Sep.

2.

NY-ESO-1 expression in DCIS: A new predictor of good prognosis.

Coombes RC, Caballero OL, Shousha S, Ghaem-Maghami S, Woodley-Barker L, Wilhelm-Benartzi CS, Neville AM.

Oncoscience. 2017 Apr 28;4(3-4):33-40. doi: 10.18632/oncoscience.348. eCollection 2017 Mar.

3.

Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP.

Lu M, Breyssens H, Salter V, Zhong S, Hu Y, Baer C, Ratnayaka I, Sullivan A, Brown NR, Endicott J, Knapp S, Kessler BM, Middleton MR, Siebold C, Jones EY, Sviderskaya EV, Cebon J, John T, Caballero OL, Goding CR, Lu X.

Cancer Cell. 2016 Nov 14;30(5):822-823. doi: 10.1016/j.ccell.2016.09.019. No abstract available.

4.

Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial-Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity.

Yao J, Caballero OL, Huang Y, Lin C, Rimoldi D, Behren A, Cebon JS, Hung MC, Weinstein JN, Strausberg RL, Zhao Q.

Cancer Immunol Res. 2016 Jun;4(6):552-61. doi: 10.1158/2326-6066.CIR-15-0255. Epub 2016 Apr 4.

5.

Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target.

Shantha Kumara H, Kirchoff D, Caballero OL, Su T, Ahmed A, Herath SA, Njoh L, Cekic V, Simpson AJ, Cordon-Cardo C, Whelan RL.

Oncoscience. 2015 Jul 1;2(6):607-14. eCollection 2015.

6.

Expression of Cancer/Testis genes in ductal carcinoma in situ and benign lesions of the breast.

Caballero OL, Shousha S, Zhao Q, Simpson AJG, Coombes RC, Neville AM.

Oncoscience. 2013 Dec 12;1(1):14-20. eCollection 2014.

7.

CD99 is upregulated in placenta and astrocytomas with a differential subcellular distribution according to the malignancy stage.

Úrias U, Marie SK, Uno M, da Silva R, Evagelinellis MM, Caballero OL, Stevenson BJ, Silva WA Jr, Simpson AJ, Oba-Shinjo SM.

J Neurooncol. 2014 Aug;119(1):59-70. doi: 10.1007/s11060-014-1462-x. Epub 2014 May 6.

PMID:
24797829
8.

NY-ESO-1 expression in meningioma suggests a rationale for new immunotherapeutic approaches.

Baia GS, Caballero OL, Ho JS, Zhao Q, Cohen T, Binder ZA, Salmasi V, Gallia GL, Quinones-Hinojosa A, Olivi A, Brem H, Burger P, Strausberg RL, Simpson AJ, Eberhart CG, Riggins GJ.

Cancer Immunol Res. 2013 Nov;1(5):296-302. doi: 10.1158/2326-6066.CIR-13-0029. Epub 2013 Aug 5.

9.

Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers.

Yao J, Caballero OL, Yung WK, Weinstein JN, Riggins GJ, Strausberg RL, Zhao Q.

Cancer Immunol Res. 2014 Apr;2(4):371-9. doi: 10.1158/2326-6066.CIR-13-0088. Epub 2013 Nov 25.

10.

Vaccines and early breast cancer.

Caballero OL, Simpson AJ, Neville AM.

Cell Cycle. 2014;13(9):1359. doi: 10.4161/cc.28747. Epub 2014 Apr 3. No abstract available.

11.

Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cells.

Pagotto A, Caballero OL, Volkmar N, Devalle S, Simpson AJ, Lu X, Christianson JC.

PLoS One. 2013 Dec 10;8(12):e83212. doi: 10.1371/journal.pone.0083212. eCollection 2013.

12.

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.

Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, Teichmann SA, Janowitz T, Jodrell DI, Tuveson DA, Fearon DT.

Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7. doi: 10.1073/pnas.1320318110. Epub 2013 Nov 25.

13.

A comprehensive promoter landscape identifies a novel promoter for CD133 in restricted tissues, cancers, and stem cells.

Sompallae R, Hofmann O, Maher CA, Gedye C, Behren A, Vitezic M, Daub CO, Devalle S, Caballero OL, Carninci P, Hayashizaki Y, Lawlor ER, Cebon J, Hide W.

Front Genet. 2013 Oct 29;4:209. doi: 10.3389/fgene.2013.00209. eCollection 2013.

14.

Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors.

Anaka M, Hudson C, Lo PH, Do H, Caballero OL, Davis ID, Dobrovic A, Cebon J, Behren A.

BMC Med Genomics. 2013 Oct 11;6:40. doi: 10.1186/1755-8794-6-40.

15.

Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia.

Roberts EW, Deonarine A, Jones JO, Denton AE, Feig C, Lyons SK, Espeli M, Kraman M, McKenna B, Wells RJ, Zhao Q, Caballero OL, Larder R, Coll AP, O'Rahilly S, Brindle KM, Teichmann SA, Tuveson DA, Fearon DT.

J Exp Med. 2013 Jun 3;210(6):1137-51. doi: 10.1084/jem.20122344. Epub 2013 May 27.

16.

Effects of CT-Xp gene knock down in melanoma cell lines.

Caballero OL, Cohen T, Gurung S, Chua R, Lee P, Chen YT, Jat P, Simpson AJ.

Oncotarget. 2013 Apr;4(4):531-41.

17.

Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP.

Lu M, Breyssens H, Salter V, Zhong S, Hu Y, Baer C, Ratnayaka I, Sullivan A, Brown NR, Endicott J, Knapp S, Kessler BM, Middleton MR, Siebold C, Jones EY, Sviderskaya EV, Cebon J, John T, Caballero OL, Goding CR, Lu X.

Cancer Cell. 2013 May 13;23(5):618-33. doi: 10.1016/j.ccr.2013.03.013. Epub 2013 Apr 25. Erratum in: Cancer Cell. 2016 Nov 14;30(5):822-823.

18.

Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas.

Zhao Q, Caballero OL, Davis ID, Jonasch E, Tamboli P, Yung WK, Weinstein JN; Kenna Shaw for TCGA research network, Strausberg RL, Yao J.

Clin Cancer Res. 2013 May 1;19(9):2460-72. doi: 10.1158/1078-0432.CCR-12-3708. Epub 2013 Feb 26.

19.

MAGE-A3 is highly expressed in a subset of colorectal cancer patients.

Shantha Kumara HM, Grieco MJ, Caballero OL, Su T, Ahmed A, Ritter E, Gnjatic S, Cekic V, Old LJ, Simpson AJ, Cordon-Cardo C, Whelan RL.

Cancer Immun. 2012;12:16. Epub 2012 Dec 28.

20.

Differential evolution of MAGE genes based on expression pattern and selection pressure.

Zhao Q, Caballero OL, Simpson AJ, Strausberg RL.

PLoS One. 2012;7(10):e48240. doi: 10.1371/journal.pone.0048240. Epub 2012 Oct 25.

21.

The Hippo signaling pathway and translational opportunities for brain cancers.

Baia GS, Caballero OL, Riggins GJ.

CNS Oncol. 2012 Nov;1(2):113-5. doi: 10.2217/cns.12.18. No abstract available.

22.

Yes-associated protein 1 is activated and functions as an oncogene in meningiomas.

Baia GS, Caballero OL, Orr BA, Lal A, Ho JS, Cowdrey C, Tihan T, Mawrin C, Riggins GJ.

Mol Cancer Res. 2012 Jul;10(7):904-13. doi: 10.1158/1541-7786.MCR-12-0116. Epub 2012 May 22.

23.

Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells.

Tsuji T, Matsuzaki J, Caballero OL, Jungbluth AA, Ritter G, Odunsi K, Old LJ, Gnjatic S.

J Immunol. 2012 Apr 15;188(8):3851-8. doi: 10.4049/jimmunol.1103269. Epub 2012 Mar 16.

24.

Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer.

Hon GC, Hawkins RD, Caballero OL, Lo C, Lister R, Pelizzola M, Valsesia A, Ye Z, Kuan S, Edsall LE, Camargo AA, Stevenson BJ, Ecker JR, Bafna V, Strausberg RL, Simpson AJ, Ren B.

Genome Res. 2012 Feb;22(2):246-58. doi: 10.1101/gr.125872.111. Epub 2011 Dec 7.

25.

Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.

de Carvalho F, Costa ET, Camargo AA, Gregorio JC, Masotti C, Andrade VC, Strauss BE, Caballero OL, Atanackovic D, Colleoni GW.

PLoS One. 2011;6(11):e27707. doi: 10.1371/journal.pone.0027707. Epub 2011 Nov 16.

26.

Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA.

Ma Y, Kowolik CM, Swiderski PM, Kortylewski M, Yu H, Horne DA, Jove R, Caballero OL, Simpson AJ, Lee FT, Pillay V, Scott AM.

ACS Chem Biol. 2011 Sep 16;6(9):962-70. doi: 10.1021/cb200176v. Epub 2011 Jul 26.

27.

Distinct patterns of somatic alterations in a lymphoblastoid and a tumor genome derived from the same individual.

Galante PA, Parmigiani RB, Zhao Q, Caballero OL, de Souza JE, Navarro FC, Gerber AL, Nicolás MF, Salim AC, Silva AP, Edsall L, Devalle S, Almeida LG, Ye Z, Kuan S, Pinheiro DG, Tojal I, Pedigoni RG, de Sousa RG, Oliveira TY, de Paula MG, Ohno-Machado L, Kirkness EF, Levy S, da Silva WA Jr, Vasconcelos AT, Ren B, Zago MA, Strausberg RL, Simpson AJ, de Souza SJ, Camargo AA.

Nucleic Acids Res. 2011 Aug;39(14):6056-68. doi: 10.1093/nar/gkr221. Epub 2011 Apr 14.

28.

Activation of nuclear factor-kappa B signalling promotes cellular senescence.

Rovillain E, Mansfield L, Caetano C, Alvarez-Fernandez M, Caballero OL, Medema RH, Hummerich H, Jat PS.

Oncogene. 2011 May 19;30(20):2356-66. doi: 10.1038/onc.2010.611. Epub 2011 Jan 17.

29.

Systematic detection of putative tumor suppressor genes through the combined use of exome and transcriptome sequencing.

Zhao Q, Kirkness EF, Caballero OL, Galante PA, Parmigiani RB, Edsall L, Kuan S, Ye Z, Levy S, Vasconcelos AT, Ren B, de Souza SJ, Camargo AA, Simpson AJ, Strausberg RL.

Genome Biol. 2010;11(11):R114. doi: 10.1186/gb-2010-11-11-r114. Epub 2010 Nov 25.

30.

Frequent MAGE mutations in human melanoma.

Caballero OL, Zhao Q, Rimoldi D, Stevenson BJ, Svobodová S, Devalle S, Röhrig UF, Pagotto A, Michielin O, Speiser D, Wolchok JD, Liu C, Pejovic T, Odunsi K, Brasseur F, Van den Eynde BJ, Old LJ, Lu X, Cebon J, Strausberg RL, Simpson AJ.

PLoS One. 2010 Sep 16;5(9). pii: e12773. doi: 10.1371/journal.pone.0012773. Erratum in: PLoS One. 2010;5(11). doi: 10.1371/annotation/3ee2788f-0c44-429f-85c3-d626c9fedc21.

31.

Dissecting the transcriptional networks underlying breast cancer: NR4A1 reduces the migration of normal and breast cancer cell lines.

Alexopoulou AN, Leao M, Caballero OL, Da Silva L, Reid L, Lakhani SR, Simpson AJ, Marshall JF, Neville AM, Jat PS.

Breast Cancer Res. 2010;12(4):R51. doi: 10.1186/bcr2610. Epub 2010 Jul 19.

32.

Number of expressed cancer/testis antigens identifies focal adhesion pathway genes as possible targets for multiple myeloma therapy.

Andrade VC, Vettore AL, Panepucci RA, Almeida MS, Yamamoto M, De Carvalho F, Caballero OL, Zago MA, Colleoni GW.

Leuk Lymphoma. 2010 Aug;51(8):1543-9. doi: 10.3109/10428194.2010.491136.

PMID:
20528248
33.

Helicobacter pylori and EBV in gastric carcinomas: methylation status and microsatellite instability.

Ferrasi AC, Pinheiro NA, Rabenhorst SH, Caballero OL, Rodrigues MA, de Carvalho F, Leite CV, Ferreira MV, Barros MA, Pardini MI.

World J Gastroenterol. 2010 Jan 21;16(3):312-9.

34.

Cancer/testis (CT) antigens: potential targets for immunotherapy.

Caballero OL, Chen YT.

Cancer Sci. 2009 Nov;100(11):2014-21. doi: 10.1111/j.1349-7006.2009.01303.x. Epub 2009 Aug 1. Review.

35.

Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer.

Tchabo NE, Mhawech-Fauceglia P, Caballero OL, Villella J, Beck AF, Miliotto AJ, Liao J, Andrews C, Lele S, Old LJ, Odunsi K.

Cancer Immun. 2009 Aug 26;9:6.

36.

CT-X antigen expression in human breast cancer.

Grigoriadis A, Caballero OL, Hoek KS, da Silva L, Chen YT, Shin SJ, Jungbluth AA, Miller LD, Clouston D, Cebon J, Old LJ, Lakhani SR, Simpson AJ, Neville AM.

Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13493-8. doi: 10.1073/pnas.0906840106. Epub 2009 Jul 27.

37.

Thermal conductivity and phase separation of the crust of accreting neutron stars.

Horowitz CJ, Caballero OL, Berry DK.

Phys Rev E Stat Nonlin Soft Matter Phys. 2009 Feb;79(2 Pt 2):026103. Epub 2009 Feb 3.

PMID:
19391802
38.

Frequency and prognostic relevance of cancer testis antigen 45 expression in multiple myeloma.

Andrade VC, Vettore AL, Regis Silva MR, Felix RS, Almeida MS, de Carvalho F, Zago MA, Caballero OL, Simpson AJ, Colleoni GW.

Exp Hematol. 2009 Apr;37(4):446-9. doi: 10.1016/j.exphem.2008.12.003. Epub 2009 Feb 10.

PMID:
19211183
39.

Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell line.

Zhao Q, Caballero OL, Levy S, Stevenson BJ, Iseli C, de Souza SJ, Galante PA, Busam D, Leversha MA, Chadalavada K, Rogers YH, Venter JC, Simpson AJ, Strausberg RL.

Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1886-91. doi: 10.1073/pnas.0812945106. Epub 2009 Jan 30.

40.

SAGE analysis highlights the importance of p53csv, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis.

Felix RS, Colleoni GW, Caballero OL, Yamamoto M, Almeida MS, Andrade VC, Chauffaille Mde L, Silva WA Jr, Begnami MD, Soares FA, Simpson AJ, Zago MA, Vettore AL.

Cancer Lett. 2009 Jun 8;278(1):41-8. doi: 10.1016/j.canlet.2008.12.022. Epub 2009 Jan 25.

PMID:
19171422
41.

Genome-wide analysis of cancer/testis gene expression.

Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger A, Lehvaslaiho M, Carninci P, Hayashizaki Y, Jongeneel CV, Simpson AJ, Old LJ, Hide W.

Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20422-7. doi: 10.1073/pnas.0810777105. Epub 2008 Dec 16.

42.

Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer.

Brait M, Begum S, Carvalho AL, Dasgupta S, Vettore AL, Czerniak B, Caballero OL, Westra WH, Sidransky D, Hoque MO.

Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2786-94. doi: 10.1158/1055-9965.EPI-08-0192.

43.

CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens.

Almeida LG, Sakabe NJ, deOliveira AR, Silva MC, Mundstein AS, Cohen T, Chen YT, Chua R, Gurung S, Gnjatic S, Jungbluth AA, Caballero OL, Bairoch A, Kiesler E, White SL, Simpson AJ, Old LJ, Camargo AA, Vasconcelos AT.

Nucleic Acids Res. 2009 Jan;37(Database issue):D816-9. doi: 10.1093/nar/gkn673. Epub 2008 Oct 5.

44.

ECSA/DPPA2 is an embryo-cancer antigen that is coexpressed with cancer-testis antigens in non-small cell lung cancer.

John T, Caballero OL, Svobodová SJ, Kong A, Chua R, Browning J, Fortunato S, Deb S, Hsu M, Gedye CA, Davis ID, Altorki N, Simpson AJ, Chen YT, Monk M, Cebon JS.

Clin Cancer Res. 2008 Jun 1;14(11):3291-8. doi: 10.1158/1078-0432.CCR-07-1322.

45.

Cancer-testis (CT) antigen expression in medulloblastoma.

Oba-Shinjo SM, Caballero OL, Jungbluth AA, Rosemberg S, Old LJ, Simpson AJ, Marie SK.

Cancer Immun. 2008 Apr 22;8:7.

46.

Aberrant promoter methylation can be useful as a marker of recurrent disease in patients with cervical intraepithelial neoplasia grade III.

Terra AP, Murta EF, Maluf PJ, Caballero OL, Brait M, Adad SJ.

Tumori. 2007 Nov-Dec;93(6):572-9.

PMID:
18338492
47.

Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas.

Yin BW, Kiyamova R, Chua R, Caballero OL, Gout I, Gryshkova V, Bhaskaran N, Souchelnytskyi S, Hellman U, Filonenko V, Jungbluth AA, Odunsi K, Lloyd KO, Old LJ, Ritter G.

Cancer Immun. 2008 Feb 6;8:3.

48.

Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients.

Andrade VC, Vettore AL, Felix RS, Almeida MS, Carvalho F, Oliveira JS, Chauffaille ML, Andriolo A, Caballero OL, Zago MA, Colleoni GW.

Cancer Immun. 2008 Feb 1;8:2.

49.

PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses.

Silva WA Jr, Gnjatic S, Ritter E, Chua R, Cohen T, Hsu M, Jungbluth AA, Altorki NK, Chen YT, Old LJ, Simpson AJ, Caballero OL.

Cancer Immun. 2007 Nov 6;7:18.

50.

Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas.

Marie SK, Okamoto OK, Uno M, Hasegawa AP, Oba-Shinjo SM, Cohen T, Camargo AA, Kosoy A, Carlotti CG Jr, Toledo S, Moreira-Filho CA, Zago MA, Simpson AJ, Caballero OL.

Int J Cancer. 2008 Feb 15;122(4):807-15.

Supplemental Content

Loading ...
Support Center